Product Code: A17078
The global intravenous solutions market was valued at $11,857.7 million in 2021, and is projected to reach $26,558.4 million by 2031, registering a CAGR of 8.3% from 2022 to 2031.
IV solutions are specially formulated liquids that are injected into a vein to prevent or treat dehydration. They are used in people of all ages who are sick, injured and dehydrated from exercise, heat and those who are undergoing surgery. Intravenous rehydration is a simple, safe and common procedure with a low risk of complications. They are injected into a person's veins through an IV (intravenous) tube. They prevent or treat dehydration and electrolyte imbalances. There are two types of intravenous fluids that include, crystalloid solutions and colloids. Crystalloid solutions contain small dissolved molecules that pass easily from the bloodstream into tissues and cells. Some of the examples of it include normal saline, which is salt in water, and D5W, which is dextrose (sugar) in water. Moreover, lactated Ringer's, which contains sodium, chloride, potassium, calcium and lactate can also be included in the crystalloid solutions. Colloids are large molecules that can't easily pass through cell membranes and are more likely to stay in the blood vessels. Some of the examples include albumin and hetastarch solutions.
The global intravenous solutions market is anticipated to show significant market growth during the forecast period, owing to increase in the prevalence of malnutrition, the faster response time and higher efficacy associated with intravenous solution therapy and surge in the geriatric population. Furthermore, increase in prevalence of cancer and rise in natality rate are considerably contributing toward the market growth. However, lack of experienced healthcare professionals and complications of intravenous administration therapy are negatively impacting the market growth. Conversely, the high growth opportunities in emerging markets offers the lucrative opportunities for the growth of the market.
The intravenous solutions market is segmented on the basis of type, composition, end user, and region. By type, the market is classified into partial parenteral nutrition and total parenteral nutrition. Furthermore, the partial parenteral nutrition is sub-classified as pediatric and adult. Also, the total parenteral nutrition is sub-classified as pediatric and adult. By composition, the market is classified into carbohydrates, vitamins and minerals, single dose amino acids, parenteral lipid emulsion and others. By end user, the market is classified into hospitals and clinics, ambulatory surgery centers, home care settings. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, Taiwan and Rest of Asia-Pacific), and LAMEA (Brazil, Turkey, Venezuela, South Africa, Saudi Arabia, and Rest of LAMEA).
The major companies profiled in the report include: Amanta Healthcare Ltd., Axa Parenterals Ltd, B. Braun Melsungen AG, Baxter International Inc., Becton, Dickinson and Company, Eurolife Healthcare Pvt Ltd, Fresenius Kabi AG, Grifols S.A., Henry Schein Inc., ICU Medical, Inc., JW Life Science, OtsUKa Pharmaceutical Co.,Ltd., Pfizer, Inc., Salius Pharma Private Limited , Sichuan Kelun Pharmaceutical Co. Ltd., Soxa Formulations & Research Pvt. Ltd., Vifor Pharma Management Ltd.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the intravenous solutions market analysis from 2021 to 2031 to identify the prevailing intravenous solutions market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the intravenous solutions market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global intravenous solutions market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
- Partial Parenteral Nutrition
- Age Group
- Pediatric
- Adult
- Total Parenteral Nutrition
- Age Group
- Pediatric
- Adult
By Composition
- Carbohydrates
- Vitamins and Minerals
- Single Dose Amino Acids
- Parenteral Lipid Emulsion
- Others
By End Users
- Hospitals and Clinics
- Ambulatory Surgery Centers
- Home care settings
By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Taiwan
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Turkey
- Venezuela
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Amanta Healthcare Ltd.
- Axa Parenterals Ltd.
- B. Braun Melsungen AG
- Baxter International Inc.
- Becton, Dickinson and Company
- Eurolife Healthcare Pvt Ltd.
- Fresenius Kabi AG
- Grifols S.A
- Henry Schein Inc.
- ICU Medical, Inc.
- JW Life Science
- Otsuka Pharmaceutical Co., Ltd.
- Pfizer, Inc.
- Salius Pharma Private Limited
- Sichuan Kelun Pharmaceutical Co. Ltd
- Soxa Formulations & Research (Pvt.) Ltd.
- Vifor Pharma Management Ltd.
TABLE OF CONTENTS
CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter's five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: INTRAVENOUS SOLUTIONS MARKET, BY TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Partial Parenteral Nutrition
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.2.4 Partial Parenteral Nutrition Intravenous Solutions Market by Age Group
- 4.3 Total Parenteral Nutrition
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.3.4 Total Parenteral Nutrition Intravenous Solutions Market by Age Group
CHAPTER 5: INTRAVENOUS SOLUTIONS MARKET, BY COMPOSITION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Carbohydrates
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Vitamins and Minerals
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Single Dose Amino Acids
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- 5.5 Parenteral Lipid Emulsion
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country
- 5.6 Others
- 5.6.1 Key market trends, growth factors and opportunities
- 5.6.2 Market size and forecast, by region
- 5.6.3 Market analysis by country
CHAPTER 6: INTRAVENOUS SOLUTIONS MARKET, BY END USERS
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Hospitals and Clinics
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Ambulatory Surgery Centers
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Home care settings
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
CHAPTER 7: INTRAVENOUS SOLUTIONS MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Type
- 7.2.3 North America Market size and forecast, by Composition
- 7.2.4 North America Market size and forecast, by End Users
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Type
- 7.2.5.1.2 Market size and forecast, by Composition
- 7.2.5.1.3 Market size and forecast, by End Users
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Type
- 7.2.5.2.2 Market size and forecast, by Composition
- 7.2.5.2.3 Market size and forecast, by End Users
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Type
- 7.2.5.3.2 Market size and forecast, by Composition
- 7.2.5.3.3 Market size and forecast, by End Users
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Type
- 7.3.3 Europe Market size and forecast, by Composition
- 7.3.4 Europe Market size and forecast, by End Users
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Type
- 7.3.5.1.2 Market size and forecast, by Composition
- 7.3.5.1.3 Market size and forecast, by End Users
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Type
- 7.3.5.2.2 Market size and forecast, by Composition
- 7.3.5.2.3 Market size and forecast, by End Users
- 7.3.5.3 UK
- 7.3.5.3.1 Market size and forecast, by Type
- 7.3.5.3.2 Market size and forecast, by Composition
- 7.3.5.3.3 Market size and forecast, by End Users
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Type
- 7.3.5.4.2 Market size and forecast, by Composition
- 7.3.5.4.3 Market size and forecast, by End Users
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Type
- 7.3.5.5.2 Market size and forecast, by Composition
- 7.3.5.5.3 Market size and forecast, by End Users
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Type
- 7.3.5.6.2 Market size and forecast, by Composition
- 7.3.5.6.3 Market size and forecast, by End Users
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Composition
- 7.4.4 Asia-Pacific Market size and forecast, by End Users
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Market size and forecast, by Type
- 7.4.5.1.2 Market size and forecast, by Composition
- 7.4.5.1.3 Market size and forecast, by End Users
- 7.4.5.2 China
- 7.4.5.2.1 Market size and forecast, by Type
- 7.4.5.2.2 Market size and forecast, by Composition
- 7.4.5.2.3 Market size and forecast, by End Users
- 7.4.5.3 India
- 7.4.5.3.1 Market size and forecast, by Type
- 7.4.5.3.2 Market size and forecast, by Composition
- 7.4.5.3.3 Market size and forecast, by End Users
- 7.4.5.4 Australia
- 7.4.5.4.1 Market size and forecast, by Type
- 7.4.5.4.2 Market size and forecast, by Composition
- 7.4.5.4.3 Market size and forecast, by End Users
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Type
- 7.4.5.5.2 Market size and forecast, by Composition
- 7.4.5.5.3 Market size and forecast, by End Users
- 7.4.5.6 Taiwan
- 7.4.5.6.1 Market size and forecast, by Type
- 7.4.5.6.2 Market size and forecast, by Composition
- 7.4.5.6.3 Market size and forecast, by End Users
- 7.4.5.7 Rest of Asia-Pacific
- 7.4.5.7.1 Market size and forecast, by Type
- 7.4.5.7.2 Market size and forecast, by Composition
- 7.4.5.7.3 Market size and forecast, by End Users
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Type
- 7.5.3 LAMEA Market size and forecast, by Composition
- 7.5.4 LAMEA Market size and forecast, by End Users
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Type
- 7.5.5.1.2 Market size and forecast, by Composition
- 7.5.5.1.3 Market size and forecast, by End Users
- 7.5.5.2 Turkey
- 7.5.5.2.1 Market size and forecast, by Type
- 7.5.5.2.2 Market size and forecast, by Composition
- 7.5.5.2.3 Market size and forecast, by End Users
- 7.5.5.3 Venezuela
- 7.5.5.3.1 Market size and forecast, by Type
- 7.5.5.3.2 Market size and forecast, by Composition
- 7.5.5.3.3 Market size and forecast, by End Users
- 7.5.5.4 Saudi Arabia
- 7.5.5.4.1 Market size and forecast, by Type
- 7.5.5.4.2 Market size and forecast, by Composition
- 7.5.5.4.3 Market size and forecast, by End Users
- 7.5.5.5 South Africa
- 7.5.5.5.1 Market size and forecast, by Type
- 7.5.5.5.2 Market size and forecast, by Composition
- 7.5.5.5.3 Market size and forecast, by End Users
- 7.5.5.6 Rest of LAMEA
- 7.5.5.6.1 Market size and forecast, by Type
- 7.5.5.6.2 Market size and forecast, by Composition
- 7.5.5.6.3 Market size and forecast, by End Users
CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
CHAPTER 9: COMPANY PROFILES
- 9.1 Amanta Healthcare Ltd.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Axa Parenterals Ltd.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 B. Braun Melsungen AG
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Baxter International Inc.
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Becton, Dickinson and Company
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Eurolife Healthcare Pvt Ltd.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Fresenius Kabi AG
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Grifols S.A
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Henry Schein Inc.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 ICU Medical, Inc.
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- 9.11 JW Life Science
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
- 9.12 Otsuka Pharmaceutical Co., Ltd.
- 9.12.1 Company overview
- 9.12.2 Company snapshot
- 9.12.3 Operating business segments
- 9.12.4 Product portfolio
- 9.12.5 Business performance
- 9.12.6 Key strategic moves and developments
- 9.13 Pfizer, Inc.
- 9.13.1 Company overview
- 9.13.2 Company snapshot
- 9.13.3 Operating business segments
- 9.13.4 Product portfolio
- 9.13.5 Business performance
- 9.13.6 Key strategic moves and developments
- 9.14 Salius Pharma Private Limited
- 9.14.1 Company overview
- 9.14.2 Company snapshot
- 9.14.3 Operating business segments
- 9.14.4 Product portfolio
- 9.14.5 Business performance
- 9.14.6 Key strategic moves and developments
- 9.15 Sichuan Kelun Pharmaceutical Co. Ltd
- 9.15.1 Company overview
- 9.15.2 Company snapshot
- 9.15.3 Operating business segments
- 9.15.4 Product portfolio
- 9.15.5 Business performance
- 9.15.6 Key strategic moves and developments
- 9.16 Soxa Formulations & Research (Pvt.) Ltd.
- 9.16.1 Company overview
- 9.16.2 Company snapshot
- 9.16.3 Operating business segments
- 9.16.4 Product portfolio
- 9.16.5 Business performance
- 9.16.6 Key strategic moves and developments
- 9.17 Vifor Pharma Management Ltd.
- 9.17.1 Company overview
- 9.17.2 Company snapshot
- 9.17.3 Operating business segments
- 9.17.4 Product portfolio
- 9.17.5 Business performance
- 9.17.6 Key strategic moves and developments